Valuation: Prothena Corporation plc

Market Cap 425M 369M 345M 317M 597M 40.52B 607M 4.07B 1.59B 20.21B 1.6B 1.56B 66.65B P/E 2026 *
-113x
P/E 2027 * -8.25x
Enterprise Value 425M 369M 345M 317M 597M 40.52B 607M 4.07B 1.59B 20.21B 1.6B 1.56B 66.65B EV / Sales 2026 *
5.1x
EV / Sales 2027 * 19.3x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.22%
1 week-4.83%
Current month+1.97%
1 month-12.84%
3 months-23.26%
6 months-5.69%
Current year-13.30%
1 week 8
Extreme 8
8.78
1 month 8
Extreme 8
10.02
Current year 7.73
Extreme 7.73
11.8
1 year 6.7
Extreme 6.7
11.8
3 years 4.32
Extreme 4.32
70.09
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Sell

General Counsel

-8,386 0.0160%
29/07/26 Sell

Executive/Senior Manager

-7,662 0.0146%
28/07/26 Fiscal year

Controller/Auditor

45,000 0.0860%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-4.83%+19.31%-87.55% 425M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-8.56%+22.91%+58.73% 53.6B
+2.67%+3.03%-14.71%-12.00% 22.91B
-2.02%-7.19%-12.62%+338.85% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-3.25%+30.55%-29.84% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+1.83%-3.51%+46.29%+159.39% 13.33B
Average +1.16%-2.41%+36.02%+137.95% 23.43B
Weighted average by Cap. +0.12%-1.71%+30.90%+121.02%

Financials

2026 *2027 *
Net sales 83.32M 72.41M 67.61M 62.06M 117M 7.94B 119M 797M 312M 3.96B 313M 306M 13.06B 22M 19.12M 17.85M 16.39M 30.9M 2.1B 31.44M 210M 82.44M 1.05B 82.64M 80.81M 3.45B
Net income 2.42M 2.11M 1.97M 1.81M 3.4M 231M 3.46M 23.18M 9.08M 115M 9.1M 8.9M 380M -55.93M -48.61M -45.38M -41.66M -78.55M -5.33B -79.92M -535M -210M -2.66B -210M -205M -8.77B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
03/08/26 $8.280 +1.97% 163,891
31/07/26 $8.120 -3.45% 545,490
30/07/26 $8.410 -1.75% 502,233
29/07/26 $8.560 0.00% 641,215
28/07/26 $8.560 -1.61% 802,255
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.120USD
Average target price
21.40USD
Spread / Average Target
+163.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock